edoc

Items where Author is "Rabaglio, M."

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Date | Item Type | Refereed
Jump to: 2022 | 2009
Number of items: 4.

2022

Sarki, M. and Ming, C. and Aissaoui, S. and Bürki, N. and Caiata-Zufferey, M. and Erlanger, T. E. and Graffeo-Galbiati, R. and Heinimann, K. and Heinzelmann-Schwarz, V. and Monnerat, C. and Probst-Hensch, N. and Rabaglio, M. and Zurrer-Härdi, U. and Chappuis, P. O. and Katapodi, M. C. and Cascade Consortium, . (2022) Intention to inform relatives, rates of cascade testing, and preference for patient-mediated communication in families concerned with hereditary breast and ovarian cancer and lynch syndrome: the Swiss CASCADE Cohort. Cancers (Basel), 14 (7). p. 1636.

Sarki, M. and Ming, C. and Aceti, M. and Fink, G. and Aissaoui, S. and Bürki, N. and Graffeo, R. and Heinimann, K. and Caiata Zufferey, M. and Monnerat, C. and Rabaglio, M. and Zürrer-Härdi, U. and Chappuis, P. O. and Katapodi, M. C. and The Cascade Consortium, . (2022) Relatives from hereditary breast and ovarian cancer and lynch syndrome families forgoing genetic testing: findings from the Swiss CASCADE cohort. J Pers Med, 12 (10). p. 1740.

Pedrazzani, C. and Aceti, M. and Schweighoffer, R. and Kaiser-Grolimund, A. and Bürki, N. and Chappuis, P. O. and Graffeo, R. and Monnerat, C. and Pagani, O. and Rabaglio, M. and Katapodi, M. C. and Caiata-Zufferey, M.. (2022) The communication chain of genetic risk: analyses of narrative data exploring proband-provider and proband-family communication in hereditary breast and ovarian cancer. J Pers Med, 12 (8). p. 1249.

2009

Rabaglio, M. and Sun, Z. and Price, K. N. and Castiglione-Gertsch, M. and Hawle, H. and Thürlimann, B. and Mouridsen, H. and Campone, M. and Forbes, J. F. and Paridaens, R. J. and Colleoni, M. and Pienkowski, T. and Nogaret, J.-M. and Láng, I. and Smith, I. and Gelber, R. D. and Goldhirsch, A. and Coates, A. S.. (2009) Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 20. pp. 1489-1498.

This list was generated on Thu Apr 25 05:45:20 2024 CEST.